Cyclophosphamide

"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Descriptor ID	D003520
MeSH Number(s)	D02.455.526.728.650.730.243 D02.705.672.500.243
Concept/Terms	Cyclophosphamide Cyclophosphamide Cytophosphane Cyclophosphamide Monohydrate Monohydrate, Cyclophosphamide Cyclophosphane Cyclophosphamide Anhydrous Cyclophosphamide Anhydrous Anhydrous, Cyclophosphamide Cyclophosphamide, (R)-Isomer Cyclophosphamide, (R)-Isomer Cyclophosphamide, (S)-Isomer Cyclophosphamide, (S)-Isomer Cytophosphan Cytophosphan Endoxan Endoxan Neosar Neosar NSC-26271 NSC-26271 NSC 26271 NSC26271 Procytox Procytox Sendoxan Sendoxan B-518 B-518 B 518 B518 Cytoxan Cytoxan

Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Halogenated [D02.455.526]
Mustard Compounds [D02.455.526.728]
Nitrogen Mustard Compounds [D02.455.526.728.650]
Phosphoramide Mustards [D02.455.526.728.650.730]
Cyclophosphamide [D02.455.526.728.650.730.243]
Organophosphorus Compounds [D02.705]
Phosphoramides [D02.705.672]
Phosphoramide Mustards [D02.705.672.500]
Cyclophosphamide [D02.705.672.500.243]

Below are MeSH descriptors whose meaning is related to "Cyclophosphamide".

Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".

Cyclophosphamide
Ifosfamide

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.

Bar chart showing 27 publications over 19 distinct years, with a maximum of 3 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	2	2
1995	0	2	2
1996	0	1	1
1997	0	1	1
1998	0	1	1
2000	0	1	1
2003	1	0	1
2004	0	1	1
2005	1	0	1
2006	0	1	1
2008	1	2	3
2011	0	2	2
2013	0	2	2
2014	0	2	2
2015	1	1	2
2017	1	0	1
2018	0	1	1
2019	0	1	1
2020	1	0	1

Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.

Al-Juhaishi T, Al-Kindi SG. Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.

View in: PubMed
Tsaliki M, Koelsch KA, Chambers A, Talsania M, Scofield RH, Chakravarty EF. Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. Int J Rheum Dis. 2021 Jan; 24(1):120-124.

View in: PubMed
Zheng L, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL, Bever KM, Mo G, Solt SE, Hoare JA, Bhattacharya R, Zhu Q, Osipov A, Onner B, Purtell KA, Cai H, Parkinson R, Hacker-Prietz A, Herman JM, Le DT, Azad NS, De Jesus-Acosta AMC, Blair AB, Kim V, Soares KC, Manos L, Cameron JL, Makary MA, Weiss MJ, Schulick RD, He J, Wolfgang CL, Thompson ED, Anders RA, Sugar E, Jaffee EM, Laheru DA. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 03 01; 27(5):1278-1286.

View in: PubMed
Al-Juhaishi T, Mckay J, Sindel A, Yazbeck V. Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020 Apr; 21(6):653-661.

View in: PubMed
Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033.

View in: PubMed
Saleem R, Rogers ZR, Neunert C, George JN. Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion. 2019 03; 59(3):921-926.

View in: PubMed
Krais JJ, Virani N, McKernan PH, Nguyen Q, Fung KM, Sikavitsas VI, Kurkjian C, Harrison RG. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Mol Cancer Ther. 2017 09; 16(9):1855-1865.

View in: PubMed
Holter-Chakrabarty JL, Pierson N, Zhang MJ, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, Epstein RB, Lazarus HM, Olsson RF, Selby GB, Williams KM, Cooke KR, Pasquini MC, McCarthy PL. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1251-7.

View in: PubMed
Teryukova NP, Pogodina ON, Ivanov VA. [Spontaneous cytotoxicity treated with anti-tumor drugs of splenocytes of rats on a model of hepatoma cell monolayer cultures]. Vopr Onkol. 2015; 61(6):1006-9.

View in: PubMed
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.

View in: PubMed

People

Explore

Similar Concepts

Top Journals